Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin

• Status: Completed
• Trial end date: 2021-01-31
• Target enrollment: 0
• Participant gender: All

Summary

study effects of rosuvastatin on markers of atherosclerosis, thrombosis, in diabetic patients treated with glimepiride/metformin without coronary artery disease.

This effect will be investigated especially on sortilin ,fetuin-A

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University; Rehab Werida
• Treatments: Glimepiride; Metformin; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus on oral therapy.

• Age 21-65 years

• Life expectancy >1 year.

• Normal lipid profile

Exclusion Criteria:

• Documented CVD

• Planned surgical intervention.

• Hypersensitivity to either of the study drug components.

• Type I diabetes.

• Current Insulin treatment.

• Hepatic impairment known hepatic failure.

• Inability to comply with study protocol.

• Active malignancy.

• Chronic inflammation (i.e. inflammatory bowel disease, lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection).

• Pregnancy, lactation or child-bearing potential.

• Chronic renal disease